Universitätsklinikum Essen, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie
Welcome,         Profile    Billing    Logout  
 12 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schadendorf, Dirk
Pivotal, NCT02938299 / 2015-002549-72: Neoadjuvant L19IL2/L19TNF- Study

Active, not recruiting
3
214
Europe
L19IL2 + L19TNF, Surgery
Philogen S.p.A.
Malignant Melanoma
10/24
12/28
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting
3
407
Europe, US, RoW
IO102-IO103, Pembrolizumab
IO Biotech, Syneos Health, Merck Sharp & Dohme LLC
Metastatic Melanoma, Unresectable Melanoma
07/25
09/27
NivoMela, NCT04309409 / 2019-002276-13: Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma

Active, not recruiting
3
374
Europe
Nivolumab, Opdivo
University Hospital, Essen, Bristol-Myers Squibb
Malignant Melanoma Stage II
09/27
01/28
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Active, not recruiting
2
220
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034
Agenus Inc.
Advanced Melanoma
05/28
05/28
ImmunoCobiVem, NCT02902029 / 2015-005097-37: Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Completed
2
186
Europe, RoW
Vemurafenib, Cobimetinib, Atezolizumab
University Hospital, Essen
Malignant Melanoma
03/24
03/24
ADMEC-O, NCT02196961 / 2013-000043-78: Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation

Active, not recruiting
2
180
Europe
Nivolumab, Opdivo
Prof. Dr. med. Dirk Schadendorf, Bristol-Myers Squibb
Merkel Cell Carcinoma
08/24
08/24
DUNCAN, NCT04362722 / 2020-003299-42: Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients

Recruiting
2
40
Europe
L19IL2 +L19TNF, bifikafusp alfa + onfekafusp alfa
Philogen S.p.A., Philogen S.p.A.
Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell
09/24
09/24
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc., Bristol-Myers Squibb
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
12/25
12/28
KEYNOTE-E40, NCT05280314: Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Recruiting
2
60
Europe, US, RoW
IO102-IO103, Pembrolizumab KEYTRUDA®
IO Biotech, Theradex, Almac, Merck Sharp & Dohme LLC
Melanoma, Squamous Cell Carcinoma of Head and Neck
04/25
01/27
Minitub, NCT01942603: Minimal SN Tumor Burden

Active, not recruiting
N/A
296
Europe
European Organisation for Research and Treatment of Cancer - EORTC
Cutaneous Melanoma
12/23
12/31
TRIM, NCT05750511: Multicenter Tissue Registry in Melanoma

Recruiting
N/A
1000
Europe
molecular tissue analysis
Dermatologic Cooperative Oncology Group
Metastatic Melanoma
02/24
02/25
Dissemond, Joachim
NCT04971161 / 2020-004960-24: Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)

Active, not recruiting
2
152
Europe
allo-APZ2-CVU, Skin-derived ABCB5-positive dermal mesenchymal stromal cells, Placebo
RHEACELL GmbH & Co. KG, FGK Clinical Research GmbH
Skin Ulcer Venous Stasis Chronic
06/26
06/26
Granulox01, NCT04181320: A Multicentre European Study to Evaluate Granulox® Used in the Treatment Pathway of Predominantly Chronic Venous Leg Ulcers (VLUs).

Terminated
N/A
128
Europe, RoW
Venous Leg Ulcer Standard of Care with Granulox, Granulox
Molnlycke Health Care AB
Venous Leg Ulcer
01/23
01/23
Lutze, Stine
NCT04971161 / 2020-004960-24: Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)

Active, not recruiting
2
152
Europe
allo-APZ2-CVU, Skin-derived ABCB5-positive dermal mesenchymal stromal cells, Placebo
RHEACELL GmbH & Co. KG, FGK Clinical Research GmbH
Skin Ulcer Venous Stasis Chronic
06/26
06/26

Download Options